From March 13 to 16 local time, the 41st Annual Congress of the European Association of Urology (EAU26), a highly anticipated event for the global urology community, was grandly held in London, UK. As a top academic conference in worldwide urology, EAU26 brought together leading specialists across the globe to discuss cutting-edge breakthroughs and innovative advances in the diagnosis and treatment of urological diseases. Novel diagnostic and therapeutic technologies for prostate cancer stood out as one of the key themes at this year’s congress.

At the congress, Professor Yang Xuecheng from the Department of Urology, The Affiliated Hospital of Qingdao University was invited to deliver a high-impact presentation on the latest progress and core data from Phase I/II clinical trials of DGPR1008 Injection, independently developed by Signdo Biotech. He systematically presented the full clinical dataset spanning safety validation in healthy volunteers to intraoperative imaging evaluation in prostate cancer patients, showcasing the strength of Chinese innovative pharmaceuticals to global peers and offering new strategies for precision diagnosis and treatment of prostate cancer.

The pivotal Phase I/II data shared by Professor Yang fully demonstrated the safety and efficacy of the agent and validated its clinical potential from healthy subjects to patients.

Notably, robust core outcomes were observed in the Phase IIa trial, as detailed below. In Phase IIa studies, the positive predictive value (PPV) for tumour tissue reached 92.31% in the 0.02 mg/kg dose group and as high as 97.44% in the 0.04 mg/kg dose group. Furthermore, the agent achieved a resection margin sensitivity of 83.33% and 100% sensitivity for lymph node detection.